Clene
Clene's revenue fell 41.5% to $0 million in fiscal 2025. Its operating margin was −11,541.5%, down from −9,676.3% a year earlier. Free cash flow was −$19 million. The diluted share count rose 41.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Clene does
Clene is a drug developer that has no approved medicine yet; in industry terms, it is clinical-stage. It makes tiny crystals of metals, such as gold, suspended in water, which it calls clean-surfaced nanotechnology (CSN) therapeutics. The company says these crystals help stressed or damaged cells make and use energy, and it is testing them in diseases of the brain and nervous system.
Its main drug candidate, CNM-Au8, is a liquid of gold nanocrystals that patients drink. Clene is studying it in amyotrophic lateral sclerosis (ALS, a fatal disease that destroys the nerves controlling muscles), multiple sclerosis (MS) and Parkinson's disease. Several trials have finished, and it still runs programs that give the drug to ALS patients who cannot join trials. It has discussed with the U.S. Food and Drug Administration whether it could apply for faster, accelerated approval in ALS; the FDA's neurology division at one point said Clene's material did not support such an application.
Clene does not sell any drug. Its small revenue comes from low-dose versions of its products sold as dietary supplements, mainly through a license and supply deal with 4Life, a supplement seller that is also a Clene shareholder and lender. Clene makes its drug candidates itself, at plants in Maryland, and had 79 employees at the end of 2025, mostly in Utah and Maryland.
Its biggest risks, as it describes them
- It has no approved drug and its future depends on CNM-Au8, which regulators may not approve or may approve only after long delays.
- It has lost money since it began and needs more funding to keep operating, which may not be available.
- Earlier trial results may not hold up in later trials, and slow patient enrollment could delay its studies.
- It makes all its drug candidates itself, so problems or damage at its own plants could halt supply.
- Even if approved, its drugs may not win acceptance from doctors, patients and insurers, or fair pricing.
Income statement
Clene lost money in fiscal 2025: a net loss of $26 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 50 | 23 | 35 | 12 | 5 |
| Debt incl. finance leases | 15 | 16 | 16 | 5 | 18 |
| Net debt (negative means net cash) | −36 | −7 | −18 | −7 | 13 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 1.2x | 5.0x | 1.2x | — | — |
| Interest coverage | −57.5x | −14.7x | −8.9x | −8.1x | −8.6x |
| Current ratio | 9.1x | 2.1x | 1.5x | 1.6x | 0.8x |
| Quick ratio | 9.1x | 2.1x | 1.5x | 1.6x | 0.8x |
Cash flow
Projections
Project Clene's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $250,904 of Clene shares on the open market, and 1 insider sold $5.8 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Reed N WilcoxDirector | Bought | 10,000 | $3.42 | $34,240 | Form 4 |
| May 12, 2026 | Chidozie Ugwumba10% owner | Sold | 73,296 | $6.20 | $454,435 | Form 4 |
| May 11, 2026 | Chidozie Ugwumba10% owner | Sold | 22,177 | $6.75 | $149,695 | Form 4 |
| May 4, 2026 | Chidozie Ugwumba10% owner | Sold | 72,884 | $6.80 | $495,611 | Form 4 |
| May 1, 2026 | Chidozie Ugwumba10% owner | Sold | 5,795 | $6.01 | $34,828 | Form 4 |
| Apr 30, 2026 | Chidozie Ugwumba10% owner | Sold | 5,736 | $6.08 | $34,875 | Form 4 |
| Apr 29, 2026 | Chidozie Ugwumba10% owner | Sold | 12,170 | $5.63 | $68,517 | Form 4 |
| Apr 28, 2026 | Chidozie Ugwumba10% owner | Sold | 1,591 | $5.90 | $9,387 | Form 4 |
| Apr 21, 2026 | Chidozie Ugwumba10% owner | Sold | 61,345 | $6.14 | $376,658 | Form 4 |
| Apr 20, 2026 | Chidozie Ugwumba10% owner | Sold | 4,318 | $6.12 | $26,426 | Form 4 |
| Apr 17, 2026 | Chidozie Ugwumba10% owner | Sold | 25,040 | $6.43 | $161,007 | Form 4 |
| Apr 16, 2026 | Chidozie Ugwumba10% owner | Sold | 7,748 | $6.40 | $49,587 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 4 of 9 | 2 of 9 |
| Rule of 40 | −4,625.5% | −6,287.8% | −9,334.0% |
| Altman Z'' | −18.27 | −40.63 | −65.16 |
| Accruals ratio | −39.9% | −45.4% | −33.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 2 of 9 | 4 of 9 | 2 of 9 |
Compare
Put Clene side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Clene | FY25 | −41.5% | −11,541.5% | −9,292.5% | — | — | 2 | |
| Lisata Therapeutics | FY25 | −83.0% | −10,711.2% | −9,398.2% | — | — | 1 | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Allarity Therapeutics | FY25 | — | −3,939.1% | −4,633.8% | — | — | — | Compare |
| Actinium Pharmaceuticals | FY25 | — | −40,274.4% | −27,426.7% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | 0 | 1 | 0 | 1 | 0 | 0 |
| Revenue growth | — | — | 251.0% | −34.6% | 38.3% | −47.7% | −41.5% |
| Gross profit | — | — | 0 | 0 | 0 | 0 | 0 |
| Research and development | 10 | 15 | 28 | 32 | 27 | 20 | 14 |
| Operating income | −16 | −20 | −50 | −48 | −40 | −33 | −23 |
| Net income | −16 | −19 | −10 | −30 | −50 | −39 | −26 |
| Diluted EPS (US$) | −18.60 | −22.00 | −3.20 | — | — | — | — |
| Diluted shares (millions) | 1 | 1 | 3 | 3 | 5 | 7 | 10 |
| Cash flow | |||||||
| Cash from operations | −13 | −19 | −35 | −39 | −30 | −21 | −18 |
| Capital expenditure | 0 | 0 | 1 | 5 | 0 | 0 | 0 |
| Free cash flow | −13 | −19 | −36 | −44 | −30 | −21 | −19 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 12 | 8 | 9 | 8 | 6 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 9 | 59 | 50 | 23 | 35 | 12 | 5 |
| Debt incl. finance leases | 1 | 8 | 15 | 16 | 16 | 5 | 18 |
| Total assets | 15 | 68 | 63 | 44 | 52 | 27 | 18 |
| Total liabilities | 10 | 68 | 50 | 41 | 39 | 36 | 36 |
| Shareholders' equity | −68 | 0 | 13 | 3 | 13 | −9 | −18 |
| Margins and ratios | |||||||
| Gross margin | — | — | 60.0% | 94.5% | 81.5% | 79.5% | 78.5% |
| Operating margin | — | −9,812.6% | −6,912.6% | −10,234.5% | −6,198.8% | −9,676.3% | −11,541.5% |
| Net margin | — | −9,357.8% | −1,347.2% | −6,325.2% | −7,569.4% | −11,520.5% | −13,086.5% |
| Free cash flow margin | — | −9,376.7% | −4,973.2% | −9,342.5% | −4,663.8% | −6,240.1% | −9,292.5% |
| Rule of 40 (growth + FCF margin) | — | — | −4,722.2% | −9,377.1% | −4,625.5% | −6,287.8% | −9,334.0% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | — | −150.6% | −377.9% | −595.5% | −1,738.4% | — |
| Return on assets | — | −46.4% | −14.8% | −55.6% | −102.2% | −98.9% | −115.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — |